Exercise Mimetic · Animal Data Only · Research Compound

SLU-PP-915: the orally active exercise-mimetic ERR agonist

📄 7 PubMed citations

A next-generation, orally bioavailable pan-ERR agonist from the same lab as SLU-PP-332: what the preclinical science shows, how it differs from 332, and the honest gaps. Animal data only; no human studies exist.

🔬 One of the first HighPeptides write-ups on the SLU-PP-332 to SLU-PP-915 jump: 915 framed specifically as the orally bioavailable next-gen ERR agonist, a side-by-side of what actually differs, and a hard "never tested in people" gate. Extends our SLU-PP-332, mitochondrial-energy and muscle-longevity coverage.
3
ERR isoforms activated (α / β / γ)
0 human trials
Human clinical data
Animal data only as of 2026
915
Orally active; chemically distinct from SLU-PP-332
Short answer

SLU-PP-915 is an orally bioavailable pan-ERR agonist that activates all 3 ERR isoforms (α, β and γ), from the Saint Louis University lab behind SLU-PP-332, studied as an exercise mimetic. In mice, injected 915 enhanced aerobic exercise capacity to a similar extent as injected 332. With 0 human trials, human safety, dosing and efficacy are unknown.

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

How It Works

🧬
Pan-ERR agonism

Activates all three estrogen-related receptors (ERRα, β, γ), orphan nuclear receptors that drive mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle, and are essential for skeletal-muscle adaptation to aerobic exercise. SLU-PP-915 was identified through the pharmacological evaluation of a new, potent pan-ERR chemical series. [PMID 37421886, 41421047]

💊
Orally bioavailable

A chemically distinct compound that, unlike SLU-PP-332, is orally bioavailable in mice. In mice, injected 915 enhanced aerobic exercise capacity (distance and duration) to a similar extent as injected 332, and oral 915 kept comparable efficacy once adjusted for systemic exposure. Oral bioavailability is the main difference from 332 that this paper reports. [PMID 41421047, 37421886]

🏃
Exercise-gene induction

In mice, 915 (like 332) robustly induces DDIT4 (an acute-aerobic-exercise gene) to levels matching or exceeding treadmill running, depending on the muscle examined, and synergizes with exercise training to further enhance DDIT4 and mitochondrial gene expression. [PMID 41421047]

❤️
Metabolic & cardiac signal

Across the SLU-PP series, pan-ERR agonism raises energy expenditure and fatty-acid oxidation and improves insulin sensitivity in metabolic-syndrome models (SLU-PP-332), and novel pan-ERR agonists ameliorate heart failure by enhancing cardiac fatty-acid metabolism and mitochondrial function. All animal data. [PMID 37739806, 37961903]

What the Data Shows

SLU-PP-915 identification & SAR
Eur J Med Chem 2023: medicinal chemistry; gene expression in vitro + in vivo
Preclinical
Oral exercise-mimetic activity
J Pharmacol Exp Ther 2026: animal data
Mouse
Heart-failure benefit (pan-ERR series)
Circulation 2024: animal data
Mouse
Anti-doping metabolite mapping
Rapid Commun Mass Spectrom 2026: in vitro
In vitro
Human clinical data
None to date; no human studies exist
0 trials

SLU-PP-915 vs SLU-PP-332: What Actually Differs

Both are pan-ERR agonist "exercise mimetics" from the same Saint Louis University lab (Burris). The meaningful difference is the route of activity, not the target. Everything below is animal / in-vitro data: neither compound has been tested in people (332 has one ex-vivo study in muscle cells from human biopsies; Source 7).

SLU-PP-915 SLU-PP-332
TargetPan-ERR agonist (ERRα/β/γ)Pan-ERR agonist (ERRα/β/γ)
Oral bioavailabilityYes, orally active in miceNo, lacks oral bioavailability in mice
Aerobic exercise capacity (mice)Increased; similar to 332 when both injected, oral comparable after adjusting for exposureIncreased (injected)
Exercise-gene inductionDDIT4 to running levels; with training, further DDIT4 + mitochondrial gene expressionUpregulates exercise-responsive genes
Human dataNo human trials; in-vitro metabolism in human liver S9/microsomes only (Source 3)No human trials; one ex-vivo study on human muscle cells (Source 7)
Approval statusDrug candidate under investigation; not an approved drug (Source 3)Drug candidate under investigation; not an approved drug (Source 3)

Key Takeaways

What We Know
  • SLU-PP-915 is a pan-ERR agonist (activates ERRα, β and γ), with the same target family and lab (Saint Louis University / Burris) as SLU-PP-332.
  • The main difference from SLU-PP-332 reported so far is oral bioavailability: in mice 915 is orally bioavailable, while 332 lacks oral bioavailability.
  • In mice, injected 915 enhances aerobic exercise capacity (running distance and duration) to a similar extent as injected 332, and oral 915 keeps comparable efficacy once adjusted for systemic exposure.
  • It induces the acute-exercise gene DDIT4 to levels matching or exceeding treadmill running (depending on the muscle), and combined with training it further enhances DDIT4 and mitochondrial gene expression.
  • Across the SLU-PP series, pan-ERR agonism improves metabolic-syndrome markers and ameliorates heart failure in animal models.
  • A sports drug-testing study has already mapped 915's in-vitro metabolites, citing its possible illicit use as a performance-enhancing substance (Source 3).
What We Don't Know
  • No human trials: SLU-PP-915 has never been tested in people. The only human-derived material is human liver S9 fraction and microsomes in an in-vitro metabolism study (Source 3). Safety, dosing and efficacy in people are entirely unknown.
  • No human dose exists. There is no established protocol, and nothing here is a dosing recommendation.
  • No long-term safety profile; the effects of chronic ERR activation in humans are uncharacterized.
  • Not approved and not a supplement. It is an early-stage research compound with no approved use.
  • Whether the mouse exercise-mimetic effect translates to human fitness, fat loss or disease outcomes is entirely unproven.

Frequently Asked Questions

What is SLU-PP-915?

SLU-PP-915 is a synthetic pan-ERR agonist ("exercise mimetic") developed at Saint Louis University — an orally bioavailable pan-ERR agonist, chemically distinct from SLU-PP-332, that activates the ERRα/β/γ nuclear receptors regulating mitochondrial and fatty-acid-oxidation genes. All published data is from animal and in-vitro studies.

How is SLU-PP-915 different from SLU-PP-332?

Same pan-ERR mechanism, but in mice 915 is orally bioavailable whereas 332 is not. In mice, injected 915 enhanced aerobic exercise capacity to a similar extent as injected 332, and oral 915 kept comparable efficacy once adjusted for systemic exposure.

Is SLU-PP-915 an exercise mimetic?

In mice it induces the acute-exercise gene DDIT4 to levels matching or exceeding treadmill running without exercise, and combined with training it further enhances DDIT4 and mitochondrial gene expression — but there is no human evidence it can replace exercise.

Is there any human data on SLU-PP-915?

No. There are no human trials — SLU-PP-915 has never been tested in people. All published work is preclinical (mouse and in-vitro); the only human-derived material is human liver S9 fraction and liver microsomes used in an in-vitro metabolism study (Source 3). Human safety, dosing and efficacy are unknown, and there is no recommended dose.

Is SLU-PP-915 detectable in drug testing?

Anti-doping researchers have already mapped its in-vitro metabolites for sports drug-testing programs, work the authors say may help uncover its illicit use as a performance-enhancing substance.

Related compound: SLU-PP-332

Swiss Chems does not list SLU-PP-915. It lists SLU-PP-332, the related compound from the same Saint Louis University lab compared above (a different compound, not SLU-PP-915). Swiss Chems sells it as capsules, but the mouse study cited above reports that SLU-PP-332 lacks oral bioavailability (Source 2), and it has no human dose or safety data. HighPeptides earns a commission on purchases. Lab-test standing and regulatory notices for every vendor we track, including this one, are on our vendors page.

SLU-PP-332 (not SLU-PP-915) at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Peer-Reviewed References

Source 1
Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915
Eur J Med Chem · 2023
PMID: 37421886
Source 2
An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
J Pharmacol Exp Ther · 2026
PMID: 41421047
Source 3
In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
Rapid Commun Mass Spectrom · 2026
PMID: 41588687
Source 4
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
Circulation · 2024
PMID: 37961903
Source 5
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
J Pharmacol Exp Ther · 2024
PMID: 37739806
Source 6
Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications
Rev Med Chil · 2026
PMID: 42024694
Source 7
Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study
Front Physiol · 2025
PMID: 40692696
Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) The Peptide Buyer’s Playbook ($19) All ebooks & guides →
Disclaimer

Educational purposes only. Not medical advice.

SLU-PP-915 is an early-stage research chemical with no human clinical data. It has not been tested in humans; there is no established dose, no safety profile, and no efficacy claim can be made for human use. Nothing here, including the vendor link above, is a recommendation to obtain or take SLU-PP-915 or SLU-PP-332; neither has a human dose or safety profile. Do not self-administer either compound.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.